3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase NA
1
Status
Terminated
1
Active not recruiting
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Conditions
Preleukemia
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Precancerous Conditions
2
Neoplasms by Histologic Type
2
Neoplasms
2
Myelodysplastic Syndromes
2
Lymphoproliferative Disorders
2
Lymphoma
2
Lymphatic Diseases
2
Leukemia, Myeloid, Acute
2
Leukemia, Myeloid
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Leukemia, Lymphoid
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Leukemia, Biphenotypic, Acute
2
Leukemia, B-Cell
2
Leukemia
2
Immunoproliferative Disorders
2
Immune System Diseases
2
Hematologic Diseases
2
Breast Neoplasms
2
Bone Marrow Diseases
2
Rectal Neoplasms
1
Primary Myelofibrosis
1
Nasopharyngeal Neoplasms
1
Nasopharyngeal Carcinoma
1
Myeloproliferative Disorders
1
Leukemia, Prolymphocytic
1
Leukemia, Myelomonocytic, Chronic
1
Fatigue
1
Interventions
Trastuzumab
304
Paclitaxel
257
Cyclophosphamide
251
Docetaxel
238
Capecitabine
176
Letrozole
163
Carboplatin
163
Fulvestrant
145
Doxorubicin
145
Bevacizumab
121
Anastrozole
106
Tamoxifen
102
exemestane
94
Vinorelbine
91
Epirubicin
90
pertuzumab
89
Gemcitabine
84
Lapatinib
80
Albumin-Bound Paclitaxel
74
Radiotherapy
71
pembrolizumab
70
palbociclib
64
130-nm albumin-bound paclitaxel
58
eribulin
56
Cisplatin
55
Everolimus
49
pyrotinib
45
Taxes
44
Goserelin
43
Neoadjuvant Therapy
40
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2
×
Breast Neoplasms
×
Patient Reported Outcome Measures
×
Clear all
NCT04272801
2025-10-22
POWER
University of Virginia
Phase 2
Active not recruiting
84 enrolled
9 charts
NCT05932667
2023-12-21
DEMETER
Institut Curie
Phase 2
Terminated
1 enrolled